Cost-effectiveness of proton radiation in the treatment of childhood medulloblastoma

Cancer

Volumn 103, Issue 4, 2005, Pages 793-801

  Lundkvist, Jonas ^a,b   Ekman, Mattias ^b   Ericsson, Suzanne Rehn ^c   Jönsson, Bengt ^d   Glimelius, Bengt ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b STOCKHOLM HEALTH ECONOMICS   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

Author keywords

Children; Cost; Medulloblastoma; Quality adjusted life years; Radiation

Indexed keywords

ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHILDHOOD CANCER; COST EFFECTIVENESS ANALYSIS; GROWTH HORMONE DEFICIENCY; HEALTH CARE COST; HEARING LOSS; HEART DISEASE; HUMAN; HYPOTHYROIDISM; INTELLIGENCE QUOTIENT; MEDULLOBLASTOMA; OSTEOPOROSIS; PATIENT SELECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTON RADIATION; QUALITY ADJUSTED LIFE YEAR; SCHOOL CHILD;

CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; HUMANS; MARKOV CHAINS; MEDULLOBLASTOMA; PROTONS; RADIOTHERAPY; RISK FACTORS;

EID: 13444303838     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20844     Document Type: Article

References (52)

1. Suit H, Goldberg S, Niemierko A, et al. Proton beams to replace photon beams in radical dose treatments. Acta Oncol. 2003;42:800-808.
2. Glimelius B, Isacsson U, Blomquist E, Grusell E, Jung B, Montelius A. Potential gains using high-energy protons for therapy of malignant tumours. Acta Oncol. 1999;38:137-145.
3. Freeman CR, Taylor RE, Kortmann RD, Carrie C. Radiotherapy for medulloblastoma in children: a perspective on current international clinical research efforts. Med Pediatr Oncol. 2002;39:99-108.
4. Kiltie AE, Lashford LS, Gattamaneni HR. Survival and late effects in medulloblastoma patients treated with craniospinal irradiation under three years old. Med Pediatr Oncol. 1997;28:348-354.
5. Sun LM, Yeh SA, Wang CJ, et al. Postoperative radiation therapy for medulloblastoma-high recurrence rate in the subfrontal region. J Neurooncol. 2002;58:77-85.
6. Gilbertson RJ. Medulloblastoma: signalling a change in treatment. Lancet Oncol. 2004;5:209-218.
7. Thomas PR, Deutsch M, Kepner JL, et al. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol. 2000;18:3004-3011.
8. Garwicz S, Anderson H, Olsen JH, et al. Second malignant neoplasms after cancer in childhood and adolescence: a population-based case-control study in the five Nordic countries. The Nordic Society for Pediatric Hematology and Oncology. The Association of the Nordic Cancer Registries. Int J Cancer. 2000;88:672-678.
9. Gurney JG, Kadan-Lottick NS, Packer RJ, et al. Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study. Cancer. 2003;97:663-673.
10. Grau C, Overgaard J. Postirradiation sensorineural hearing loss: a common but ignored late radiation complication. Int J Radiat Oncol Biol Phys. 1996;36:515-517.
11. Ris MD, Packer R, Goldwein J, Jones-Wallace D, Boyett JM. Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study. J Clin Oncol. 2001;19:3470-3476.
12. Huang E, Teh BS, Strother DR, et al. Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys. 2002;52:599-605.
13. Archambeau JO, Slater JD, Slater JM, Tangeman R. Role for proton beam irradiation in treatment of pediatric CNS malignancies. Int J Radiat Oncol Biol Phys. 1992;22:287-294.
14. Miralbell R, Lomax A, Russo M. Potential role of proton therapy in the treatment of pediatric medulloblastoma/ primitive neuro-ectodermal tumors: spinal theca irradiation. Int J Radiat Oncol Biol Phys. 1997;38:805-811.
15. Miralbell R, Lomax A, Cella L, Schneider U. Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. Int J Radiat Oncol Biol Phys. 2002;54:824-829.
16. Clair W, Adams J, Bues M, et al. Advantage of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma. Int J Radiat Oncol Biol Phys. 2004;48:727-734.
17. Sonnenberg F, Beck J. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-338.
18. Mertens AC, Yasui Y, Neglia JP, et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol. 2001;19:3163-3172.
19. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst. 2002;94:182-192.
20. Travis LB. Therapy-associated solid tumors. Acta Oncol. 2002;41:323-333.
21. Fossa SD, Aass N, Harvei S, Tretli S. Increased mortality rates in young and middle-aged patients with malignant germ cell tumours. Br J Cancer. 2004;90:607-612.
22. Palmer SL, Goloubeva O, Reddick WE, et al. Patterns of intellectual development among survivors of pediatric medulloblastoma: a longitudinal analysis. J Clin Oncol. 2001;19:2302-2308.
23. Walter AW, Mulhern RK, Gajjar A, et al. Survival and neuro-developmental outcome of young children with medulloblastoma at St. Jude Children's Research Hospital. J Clin Oncol. 1999;17:3720-3728.
24. Copeland DR, deMoor C, Moore BD III, Ater JL. Neurocognitive development of children after a cerebellar tumor in infancy: a longitudinal study. J Clin Oncol. 1999;17:3476-386.
25. Ricardi U, Corrias A, Einaudi S, et al. Thyroid dysfunction as a late effect in childhood medulloblastoma: a comparison of hyperfractionated versus conventionally fractionated craniospinal radiotherapy. Int J Radiat Oncol Biol Phys. 2001;50:1287-1294.
26. Paulino AC. Hypothyroidism in children with medulloblastoma: a comparison of 3600 and 2340 cGy craniospinal radiotherapy. Int J Radiat Oncol Biol Phys. 2002;53:543-547.
27. Mohr PE, Feldman JJ, Dunbar JL. The societal costs of severe to profound hearing loss in the United States. Policy Anal Brief H Ser. 2000;2:1-4.
28. Brosson B. Hörapparat för vuxna-nytta och kostnader, report 164. Stockholm: The Swedish Council on Technology Assessment in Health Care, 2003.
29. Schwartz J. Societal benefits of reducing lead exposure. Environ Res. 1994;66:105-124.
30. Salkever DS. Updated estimates of earnings benefits from reduced exposure of children to environmental lead. Environ Res. 1995;70:1-6.
31. LINFO. FASS Läkemedel i Sverige [Swedish drug prices]. Oslo: Läkemedelsinformation AB, 2001.
32. [No authors]. Price list. Labmedicin, Huddinge Hospital. Stockholm: 2003.
33. [No authors]. Kostnad per intagen patient. Cooperation of county councils. Stockholm, 2003.
34. Läkemedelsboken. Apoteket AB, 2001.
35. Johnell O, Kanis JA, Oden A, et al. Fracture risk following an osteoporotic fracture. Osteoporos Int. 2004;15:175-179.
36. Johnell O, Kanis JA, Oden A, et al. Mortality after osteoporotic fractures. Osteoporos Int. 2004;15:38-42.
37. Kanis JA, Johnell O, Oden A, et al. Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int. 2000;11:669-674.
38. Zethraeus N. Costs and quality of life associated with osteoporosis related fractures-based on a Swedish Pilot Study. Stockholm: Centre for Health Economics, Stockholm School of Economics, 2002.
39. Glimelius B, Bergh J, Brandt L, et al. The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types-summary and conclusions. Acta Oncol. 2001;40(2-3): 135-154.
40. Lundberg L. Health-related quality of life in Sweden [dissertation]. Uppsala: Faculty of Pharmacy, Uppsala University, 1999.
41. Bichey BG, Hoversland JM, Wynne MK, Miyamoto RT. Changes in quality of life and the cost-utility associated with cochlear implantation in patients with large vestibular aqueduct syndrome. Otol Neurotol. 2002;23:323-327.
42. Bona M, Santini F, Rivolta G, Grossi E, Grilli R. Cost effectiveness of screening for subclinical hypothyroidism in the elderly. A decision-analytical model. Pharmacoeconomics. 1998;14:209-216.
43. Burman P, Broman JE, Hetta J, et al. Quality of life in adults with growth hormone (GH) deficiency: response to treatment with recombinant human GH in a placebo-controlled 21-month trial. J Clin Endocrinol Metab. 1995;80:3585-3590.
44. Lagrou K, Xhrouet-Heinrichs D, Massa G, et al. Quality of life and retrospective perception of the effect of growth hormone treatment in adult patients with childhood growth hormone deficiency. J Pediatr Endocrinol Metab. 2001;14(Suppl 5):1249-1260; discussion, 1261-1262.
45. Li Voon Chong JS, Groves T, Foy P, Wallymahmed ME, MacFarlane IA. Elderly people with hypothalamic-pituitary disease and untreated GH deficiency: clinical outcome, body composition, lipid profiles and quality of life after 2 years compared to controls. Clin Endocrinol (Oxf). 2002;56:175-181.
46. Rosen T, Wiren L, Wilhelmsen L, Wiklund I, Bengtsson BA. Decreased psychological well-being in adult patients with growth hormone deficiency. Clin Endocrinol (Oxf). 1994;40:111-116.
47. Wallymahmed ME, Foy P, MacFarlane IA. The quality of life of adults with growth hormone deficiency: comparison with diabetic patients and control subjects. Clin Endocrinol (Oxf). 1999;51:333-338.
48. Wallymahmed ME, Foy P, Shaw D, Hutcheon R, Edwards RH, MacFarlane IA. Quality of life, body composition and muscle strength in adult growth hormone deficiency: the influence of growth hormone replacement therapy for up to 3 years. Clin Endocrinol (Oxf). 1997;47:439-446.
49. Wiren L, Whalley D, McKenna S, Wilhelmsen L. Application of a disease-specific, quality-of-life measure (QoL-AGHDA) in growth hormone-deficient adults and a random population sample in Sweden: validation of the measure by rasch analysis. Clin Endocrinol (Oxf). 2000;52:143-152.
50. Goitein M, Jermann M. The relative costs of proton and X-ray radiation therapy. Clin Oncol (R Coll Radiol). 2003;15: S37-S50.
51. Norlund A. Cost of radiotherapy. Acta Oncol. 2003;42:411-415.
52. Hakkaart-van Roijen L, Beckers A, Stevenaert A, Rutten FF. The burden of illness of hypopituitary adults with growth hormone deficiency. Pharmacoeconomics. 1998;14:395-403.